Cite
HARVARD Citation
Fizazi, K. et al. (2020). Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet oncology. 21 (11), pp. 1513-1525. [Online].